SEC Form 4 · accession 0001140361-17-031316
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Debanjan Ray
Officer — Chief Financial Officer
Period of report
Aug 9, 2017
Accepted (ET)
Aug 11, 2017 · 12:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 9, 2017 | S | 2,500 | $15.00 | D | 19,626 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.